| Literature DB >> 33643765 |
Abstract
The main aim of the paper was to determine bioactive compounds in Pleione maculata extracts using gas chromatographic technique and to investigate their drug-likeness potential using molecular docking algorithm and ADME studies on the recent intractable disease, for example, SARS-CoV-2. Pleione maculata sample was prepared for GC-MS analysis. The peak components were identified based on the NIST Library. Molecular docking was performed using PatchDock, and energy refinement was carried out using the FireDock algorithm followed by drug-likeness analysis using the SwissADME tool. The mass spectrum revealed various pharmacologically important compounds and novel compounds 8-oxatetracyclo{5.2.1.1(2,6). 1(4,10)}dodecane, 7-tert-butyl-1,9,9-trimeth, docosane, 2,4-dimethyl, kryptogenin 2,4-dinitrophenyl hydrazine, and N-decyl-alpha,D-2-deoxyglycoside which are reported for the first time. Molecular docking using PatchDock illustrates GC-MS compounds Nor-diazepam,3-{N-hydroxymethyl}aminocarbonyloxy a good docking and high binding affinity with atomic contact energy -10.95 kcal/mol against SARS-CoV-2 spike protein S2 subunit. ADME analysis predicts Nor-diazepam,3-{N-hydroxymethyl}aminocarbonyloxy and andrographolide showed very high drug-likeness parameters with no metabolism disturbances. The random control antiviral drug arabidiol revealed a lower binding affinity and lower solubility compared to bioactive compounds of P. maculata. The study depicts the first and novel report on various pharmaceutical important GC-MS bioactive compounds and molecular docking study on Pleione maculata having potential against various intractable diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13721-020-00276-1.Entities:
Keywords: Drug-likeness; Gas chromatography; Molecular docking; Pleione maculata; SARS-CoV-2
Year: 2021 PMID: 33643765 PMCID: PMC7903411 DOI: 10.1007/s13721-020-00276-1
Source DB: PubMed Journal: Netw Model Anal Health Inform Bioinform ISSN: 2192-6670
Fig. 1The 3D ribbon structures representation of SARS-CoV-2 target proteins a spike glycoprotein S2 subunit post-fusion core, b 3CL protease and c RNA-dependent RNA polymerase visualized using PyMOL
Fig. 2GC–MS compounds and positive control arabidol ligands downloaded from PubChem data bank with compound ID and visualized using PyMOL for molecular docking
Fig. 3GC–MS spectrograms showing peaks of compounds of Pleione maculata extracts (a) acetone, (b) ethanol (c) methanol extracts of (i) leave (ii) stem and (iii) root
GC–MS analysis of acetone extracts of Pleione maculata
GC–MS analysis of ethanol extracts of Pleione maculata
GC–MS analysis of methanol extracts of Pleione maculata
Docking analysis depicting the binding residues and their binding energy
| Protein Name | Drug-likeness ligands | Polar contact binding residues | Other intermolecular contact binding residues | Global energy (kcal/mol) | Attractive Vdw (kcal/mol) | Repulsive Vdw (kcal/mol) | ACE (kcal/mol) |
|---|---|---|---|---|---|---|---|
| RNA-dependent RNA-pol (6M71) | 2,4,6-Pyrimidinetrione | Cys 780, Arg 467, Leu 470, Arg 305 | All side bonded by polar contacts | − 23.59 | − 10.00 | 0.72 | − 5.79 |
| 21-Acetoxypregenelone | Ala 706, Leu 707, Asn 705 | Gly 774, Asp 135, Ala 130, Ser 709 | − 34.15 | − 20.12 | 10.12 | − 8.38 | |
| Thr 141, Leu 142 | Ala 130, Asp 126 | − 31.56 | − 12.13 | 0.87 | − 7.18 | ||
| Nor-diazepam, 3{n-hydroxymethyl}aminocarbonyloxy | Thr 556, Arg 555, Arg 624 | All side bonded by polar contact | − 35.35 | − 23.08 | 4.90 | − 3.16 | |
| Digitoxin | Lys 267, Ser 255, Thr 252 | Ser 255, Tyr 265, Thr 319 | − 79.90 | − 36.74 | 12.20 | − 22.96 | |
| DI- | Tyr 546, Val 410, Lys 141 | Lys 411, Asn 414, Gln 408 | − 44.31 | − 19.74 | 2.12 | − 11.57 | |
| 14-dodecanoic acid | Lys 411, Val 410 | Tyr 546, Ser 15, Asn 414 | − 29.99 | − 14.73 | 2.24 | − 6.96 | |
| Estra-1,3,5(10)-trien-17-beta-ol | Gln 18, Gln 19 | Ser 15, Asn 414 | − 36.68 | − 20.43 | 4.20 | − 6.57 | |
| Arachidonic amide,N-{5-hydroxy-N-Pentyl} | Tyr 268 | Lys 267 | − 46.08 | − 21.29 | 4.04 | − 12.04 | |
| 1-methylsulfanyl-9–10-dioxo-9,10-dihydro-Anthracene-2-carboxylic acid | Asp 218, Thr 206 | Tyr 217, Ile 37, Tyr 38 | − 37.97 | − 20.97 | 3.26 | − 6.72 | |
| Cholesterol margarate | Lys 391 | Thr 393, Lys 395, Asn 136 | − 70.69 | − 31.28 | 9.37 | − 21.60 | |
| Docosanoic acid | No polar contact | Ser 15, Asn 414, Tyr 546, Lys 411 | − 47.59 | − 23.22 | 8.71 | − 13.13 | |
| 26-hydroxycholesterol | Asn 781, Asp 126 | Ser 784, Lys 47, Thr 141, Lys 780 | − 42.36 | − 21.98 | 1.38 | − 7.11 | |
| Andrographolide | Leu 142, Asp 140, Tyr 129, Asn 781, Ser 709, Leu 708 | Cys 139, Asp 140, Thr 141, Lys 47 | − 37.42 | − 19.40 | 4.39 | − 8.43 | |
| 6H-purin-6-one,1,7-dihydro-2-(methylamino) | Tyr 530, Asn 534 | Asn 360, Val 342 | − 29.00 | − 12.14 | 0.14 | − 6.92 | |
| Pseduosarsasapogenin-5,20-dien | Ser 15 | Val 12, Asp 846, Asn 414, Val 12 | − 56.41 | − 29.45 | 6.51 | − 12.54 | |
| Oxiraneundecanoic acid,3-pentyl, methyl ester, cis | No polar contact | Lys 411, Ser 15, Asn 414, Val 12 | − 46.14 | − 22.77 | 5.77 | − 11.38 | |
| Pregabalin | Asn 356, Tyr 530, Asp 377 | Thr 344, Ser 343 | − 30.35 | − 13.26 | 0.32 | − 6.85 | |
| Arabidol | Asn 781, Tyr 129 | Lys 780, Ser 709, Thr 710, Ser 784 | − 41.54 | − 20.55 | 5.40 | − 9.95 | |
| 3CL Protease (6M2Q) | 2,4,6-Pyrimidinetrione | Met 6, Asp 295, Gln 127, Val 296, Arg 298 | All side bonded by Polar contacts | − 16.68 | − 7.33 | 0.09 | − 4.42 |
| 21-Acetoxypregenelone | Arg 188, Gln 184, Thr 190, Met 165, Glu 166, Leu 167, Ser 46, Thr 45 | Thr 25, Thr 24, Thr 26 | − 28.57 | − 14.64 | 8.41 | − 9.22 | |
| Asn 142 | Gly 143, Cys 145, His 163, Asn 143 | − 24.19 | − 11.51 | 2.27 | − .6.75 | ||
| Nor-diazepam, 3{n-hydroxymethyl}aminocarbonyloxy | Met 165, Glu 166, Asn 142 | Ser 46, Met 49 | − 25.73 | − 11.42 | 0.80 | − 7.19 | |
| Digitoxin | Gly 116, Tyr 154 | Asn 151, Asp 153, Tyr 154, Phe 305, Phe 294 | − 54.15 | − 27.23 | 6.90 | − 13.27 | |
| DI- | Phe 294, Gln 110, Thr 111, Thr 292 | Asp 295, Pro 293 | − 28.23 | − 14.86 | 5.07 | − 7.39 | |
| 14-dodecanoic acid | Leu 253, Leu 250, Ile 249, Pro 252 | Phe 294, Val 297, Asp 248, Asp 245 | − 18.11 | − 9.92 | 4.01 | − 5.98 | |
| Estra-1,3,5(10)-trien-17-beta-ol | Phe 294, Pro 293, Thr 111, Gln 110, His 246 | All side bonded by polar contacts | − 19.00 | − 10.41 | 3.39 | − 5.43 | |
| Arachidonic amide, | Asn 142, Gly 143 | Ser 144, Glu 166, Leu 167 | − 38.03 | − 17.95 | 5.31 | − 10.86 | |
| 1-methylsulfanyl-9–10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid | Glu 166, Met 165 | Ser 46, Thr 25, Glu 47 | − 39.16 | − 16.63 | 4.12 | − 12.29 | |
| Cholesterol margarate | Gln 110, Gln 109 | Pro 108, Gln 240 | − 40.95 | − 23.94 | 9.46 | − 9.91 | |
| Docosanoic acid | no polar contacts | Phe 294, Gln 110, Thr 111, Asp 153 | − 28.31 | − 14.82 | 1.65 | − 6.51 | |
| 26-hydroxycholesterol | His 163, Met 165, Glu 166 | Asn 142, Cys 145, Ser 46, Thr 45 | − 40.85 | − 17.40 | 4.98 | − 12.61 | |
| Andrographolide | Thr 25, Ser 46, Glu 166, Met 165 | Asn 142, His 41 | − 24.51 | − 13.53 | 7.31 | − 7.17 | |
| 6H-purin-6-one,1,7-dihydro-2-(methylamino) | Glu 166, Met 165, Leu 167, Cys 145 | His 163, Asn 142, Gly 143 | − 21.58 | − 8.97 | 2.01 | − 6.60 | |
| Pseduosarsasapogenin-5,20-dien | Thr 243, Phe 294, Thr 111, Gln 110 | Thr 242, Asp 245 | − 34.40 | − 18.57 | 6.71 | − 8.41 | |
| Oxiraneundecanoic acid,3-pentyl, methyl ester, cis | Gln 110, Gly 109 | Phe 294, Pro 293, His 246, Asr 153 | − 24.73 | − 12.67 | 1.46 | − 5.53 | |
| Pregabalin | Arg 298, Met 6 | Val 303, Thr 304, Arg 298, Gln 299 | − 20.69 | − 10.29 | 3.12 | − 6.33 | |
| Arabidol | Glu 166, Met 165, His 164 | Thr 26, Thr 25, Thr 24, Thr 45 | − 37.06 | − 16.29 | 10.23 | − 14.02 | |
| Spike glycoprotein (6LXT) | 2,4,6-Pyrimidinetrione | Val 952, Asn 955, Asn 956, Asn 953 | All side bonded by polar contact | − 26.44 | − 10.31 | 0.16 | − 6.94 |
| 21-Acetoxypregenelone | Ala 942, Ser 940, Arg 1185 | Asn 1187, Ser 943, Lys 1181, Ile 183 | − 28.10 | − 19.75 | 5.74 | − 2.22 | |
| P- menth-8(10)-en-9-ol | Leu 922 | Ile 923, Ala 924, Asn 919, Gln 920 | − 24.89 | − 11.41 | 1.94 | − 6.68 | |
| Nor-diazepam, 3{n-hydroxymethyl}aminocarbonyloxy | Ile 1198, Asn 928, Leu 1197 | Asp 1199, Asn 925 | − 36.22 | − 17.30 | 4.48 | − 10.95 | |
| Digitoxin | Ser 940, Arg 1185 | Glu 1182, Ser 943, Asp 936, Lys 1191, Gln 935 | − 63.54 | − 42.37 | 17.15 | − 8.93 | |
| DI- | Ser 940 | Ser 943, Ser 939, Lys 1181, Lys 947 | − 41.11 | − 26.75 | 5.32 | − 4.29 | |
| 14-dodecanoic acid | Ser 939 | Asn 1194, Asn 1187, Glu 1188, Glu 1195, Gln 935 | − 23.19 | − 13.50 | 1.46 | − 3.08 | |
| Estra-1,3,5(10)-trien-17-beta-ol | Ala 1190, Lys 1191 | Arg 1185, Asn 1187, Gln 935 | − 32.36 | − 19.07 | 3.90 | − 4.34 | |
| Arachidonic amide, | Lys 947 | Asp 1184, Glu 1188, Asn 1187, Asp 936, Lys 1191, Ser 939 | − 42.54 | − 27.63 | 3.87 | − 2.74 | |
| 1-methylsulfanyl-9–10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid | Asp 184, Ser 940, Arg 1185, Lys 947 | Ser 943, Ser 949 | − 31.67 | − 21.43 | 1.25 | − 0.52 | |
| Cholesterol margarate | no polar contact | Asn 1184, Asn 1187, Asp 936, Gln 935 | − 54.12 | − 32.79 | 9.27 | − 8.23 | |
| Docosanoic acid | Asn 1178, Lys 1181 | Ser 943, Ser 939, Lys 947, Gln 935 | − 37.20 | − 26.13 | 3.97 | − 2.01 | |
| 26-hydroxycholesterol | Asn 925, Gln 926, Lys 1191 | Gln 1195, Asp 936, Gly 932, Asn 928 | − 41.67 | − 20.53 | 2.58 | − 8.23 | |
| Andrographolide | Gln 920, Lys 921, Tyr 917 | Glu 1202, Val 915 | − 29.04 | − 21.14 | 20.25 | − 9.23 | |
| 6H-purin-6-one,1,7-dihydro-2-(methylamino) | Tyr 917 | Leu 1200, Asp 1199, Tyr 917 | − 19.45 | − 8.27 | 0.66 | − 5.86 | |
| Pseduosarsasapogenin-5,20-dien | Ser 939 | Ser 940, Glu 1182, Lys 1181 | − 41.80 | − 28.41 | 2.51 | − 2.20 | |
| Oxiraneundecanoic acid,3-pentyl, methyl ester, cis | Lys 1181 | Arg 1181, Asp 936, Ser 943, Ser 939 | − 34.65 | − 25.21 | 6.80 | − 2.26 | |
| Pregabalin | no polar contacts | Leu 1200, Ile 923, Ala 924 | − 27.07 | − 13.01 | 2.00 | − 6.29 | |
| Arabidiol | Arg 1185, Leu 1186, Asp 1184 | Lys 1181, Asn 1187, Ser 943 | − 29.82 | − 22.67 | 4.74 | 0.13 |
Fig. 4Molecular docking of target SARS-CoV-2 RNA-dependent RNA-polymerase (PDB ID- 6M71) with the S-CoV-2 RNA-dependent RNA polymerase (PDB ID-6M71) with the GC–MS bioactive compounds of Pleione maculata (1) oxiraneundecanoic acid,3-pentyl, methyl ester, cis (2) p-menth-8(10)-en-9-ol (3) 6H-purin-6-one,1,7-dihydro-(2-methylamino) (4) andrographolide (5) 21-acetoxypregenelone (6) 26-hydroxycholesterol (7) cholesterol margarate (8) digitoxin (9) arachidonic amide, N-{5-hydroxy-N-pentyl} (10) DI-N-decylsulfone (11) estra-1,3,5(10)-trien-beta-ol (12) docosanoic acid (13) 14-dodecanoic acid (14) Nor-diazepam,3-{N-hydroxymethyl}aminocarbonyloxy (15) pregabalin (16) 2,4,6-pyrimidinetrione (17) pseduosarsasapogenin acid, 3-pentyl, methyl ester, cis, (18) 1-methylsulfanyl-9,10-dioxo-9, 10-dihydro-anthracene-2-carboxylic acid and positive control (19) arabidiol
Fig. 5Molecular docking of target SARS-CoV-2 3CL protease (PDB ID- 6M2Q) with the GC–MS bioactive compounds of Pleione maculata (1) oxiraneundecanoic acid,3-pentyl, methyl ester, cis (2) p-menth-8(10)-en-9-ol (3) 6H-purin-6-one,1,7-dihydro-(2-methylamino) (4) andrographolide (5) 21-acetoxypregenelone (6) 26-hydroxycholesterol (7) cholesterol margarate (8) digitoxin (9) arachidonic amide, N-{5-hydroxy-N-pentyl} (10) DI-N-decylsulfone (11) estra-1,3,5(10)-trien-beta-ol (12) docosanoic acid (13) 14-dodecanoic acid (14) Nor-diazepam,3-{N-hydroxymethyl}aminocarbonyloxy (15) pregabalin (16) 2,4,6-pyrimidinetrione (17) pseduosarsasapogenin acid, 3-pentyl, methyl ester, cis, (18) 1-methylsulfanyl-9,10-dioxo-9, 10-dihydro-anthracene-2-carboxylic acid and positive control (19) arabidiol
Fig. 6Molecular docking of target SARS-CoV-2 spike glycoprotein S2 subunit (PDB ID- 6LXT) with the GC–MS bioactive compounds of Pleione maculata (1) oxiraneundecanoic acid,3-pentyl, methyl ester, cis (2) p-menth-8(10)-en-9-ol (3) 6H-purin-6-one,1,7-dihydro-(2-methylamino) (4) andrographolide (5) 21-acetoxypregenelone (6) 26-hydroxycholesterol (7) cholesterol margarate (8) digitoxin (9) arachidonic amide, N-{5-hydroxy-N-pentyl} (10) DI-N-decylsulfone (11) estra-1,3,5(10)-trien-beta-ol (12) docosanoic acid (13) 14-dodecanoic acid (14) Nor-diazepam,3-{N-hydroxymethyl}aminocarbonyloxy (15) pregabalin (16) 2,4,6-pyrimidinetrione (17) pseduosarsasapogenin acid, 3-pentyl, methyl ester cis, (18) 1-methylsulfanyl-9,10-dioxo-9, 10-dihydro-anthracene-2-carboxylic acid and positive control (19) arabidiol
Lipinski rule of five (RO5) violation
| Molecular weight | < 500 Daltons |
|---|---|
| Hydrogen bond donors | No > 5 |
| Hydrogen bond acceptors | No > 10 |
| Octanol–water partition coefficient (logP) | < 5 |
| Number of rotatable bonds | No < 10 |
Drug-likeness analysis of bioactive compounds showing good binding energy against SARS-CoV-2 proteins
| Drug-likeness compounds | Physicochemical properties (Lipinski rule of five) | Solubility | Pharmacokinetics | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MW | HB donors | HB acceptors | No of rotatable bond | Consensus log P | Log S (ESOL) | Log S (Ali) | Log S (SILICOS-IT) | GI absorption | CYP enzymes inhibitors | |
| Digitoxin | 764 | 5 | 13 | 7 | 2.61 | Moderately soluble | Moderately soluble | Moderately soluble | Low | No |
| 26-hydroxycholesterol | 402 | 2 | 2 | 6 | 5.86 | Poorly soluble | Poorly soluble | Moderately soluble | High | No |
| 1-methylsulfanyl-9,10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid | 387 | 1 | 3 | 4 | 4.10 | Moderately soluble | Poorly soluble | Poorly soluble | High | Yes |
| Arachidonic amide, | 389 | 2 | 2 | 20 | 6.27 | Moderately soluble | Poorly soluble | Poorly soluble | High | No |
| Cholesterol margarate | 639 | 0 | 2 | 22 | 12.43 | Insoluble | Insoluble | Insoluble | Low | No |
| 21-acetoxypregenolone | 374 | 1 | 4 | 4 | 3.77 | Moderately soluble | Soluble | Soluble | High | Only CYP2C9 inhibitor |
| DI- | 346 | 0 | 2 | 18 | 6.68 | Poorly soluble | Poorly soluble | Poorly soluble | Low | CYP2C9, CYP1A2 inhibitor |
| Pseduosarsasapogenin-5,20-dien | 414 | 2 | 3 | 4 | 4.86 | Moderately soluble | Moderately soluble | Moderately soluble | High | No |
| Nor-diazepam,3-{ | 373 | 2 | 5 | 5 | 2.16 | Soluble | Soluble | solUble | High | No |
| Andrographolide | 350 | 3 | 5 | 3 | 2.33 | Soluble | Soluble | Soluble | High | No |
| Pregabalin | 159 | 2 | 3 | 5 | 0.56 | Highly soluble | Highly soluble | Soluble | High | No |
| P-menth-8(10)-en-9-ol | 154 | 1 | 1 | 2 | 2.55 | Soluble | Soluble | Soluble | High | No |
| Docosanoic acid | 340 | 1 | 2 | 20 | 7.40 | Poorly soluble | Insoluble | Poorly soluble | Low | CYP1A2 inhibitor |
| Arabidol | 444 | 2 | 2 | 7 | 6.97 | Poorly soluble | Poorly soluble | Poorly soluble | Low | No |
Fig. 7SwissADME bioavailability radar of different bioactive drug-likeness molecules, where the pink areas represent each property (lipophilicity, molecular weight, solubility, and flexibility)